Pharmacy Times

NOVEMBER 2, 2023

An analysis of the REVOLUTIONIZE II study data showed that there is an unmet need for long-term outpatient treatment of hyperkalemia in patients with CKD.

139

139

Hospital Pharmacy Europe

DECEMBER 11, 2022

A purified EPA formulation lowered adverse cardiovascular events in those with coronary artery disease (CAD) compared to a control group. Statin therapy leads to a reduction of cardiovascular events in both primary and secondary prevention. in the icosapent ethyl group vs. 11.3% in the control group (p = 0.031).

Hospitals 52

Hospitals 52

Hospital Pharmacy Europe

DECEMBER 20, 2022

Elevated lipoprotein A levels appear to have an important role in modifying the level of cardiovascular risk among patients with hypertension. Higher lipoprotein A levels in patients with hypertension increases their risk of an adverse cardiovascular event according to the findings of a study by US researchers. were White, 27.5%

Hospitals 52

Hospitals 52

STAT

OCTOBER 31, 2023

The world’s hottest summer on record is now bleeding into the fall. Instead of enjoying a cool respite from the heat, millions of Americans started September enduring temperatures so high that schools were forced to close across the country.

109

109

Pharmacy Times

JULY 19, 2023

Due to the assessment of computerized tomography with criteria from 1999, the role of radiotherapy in patients with diffuse large B-cell lymphoma with bulky or extranodal disease remains undefined.

108

108

Pharmacy Times

JULY 26, 2023

The low risk of cardiovascular events was observed in all relevant subgroups, including in both males and females with HIV.

123

123

Pharmacy Times

AUGUST 31, 2023

A combination of statin therapy and antiretroviral therapy may decrease the naturally higher risk of cardiovascular disease in patients with HIV.

123

123

Pharmacy Times

FEBRUARY 7, 2024

Expert panelists provide an overview of adverse events associated with bispecific antibodies for the treatment of multiple myeloma along with best practices for monitoring and treating adverse events.

65

65

Fierce Pharma

JULY 11, 2023

The study was assessing the drug in certain patients with previously untreated diffuse large B-cell lymphoma.

40

40

Outsourcing Pharma

FEBRUARY 28, 2022

The recent Outsourcing-Pharma webinar hosted a trio of industry experts highlighting challenges, opportunities, and innovations in the rare disease realm.

98

98

STAT

APRIL 17, 2024

In one year-long Phase 3 study that looked at patients with obesity who were not on PAP therapy, a form of ventilation, those taking Zepbound experienced a reduction of 25.3 events per hour on the apnea-hypopnea index (AHI), a measure of the number of times breathing stops and becomes restricted while sleeping.

145

145

Drug Topics

FEBRUARY 13, 2024

Many patients with the condition continue to experience severe hypoglycemic events even with the use of continuous glucose monitors and other disease management tools.

169

169

Drug Topics

SEPTEMBER 18, 2023

From automated medication dispensing systems to telepharmacy services, technology can help reduce the risk of adverse patient events.

Medication Dispensing 247

Medication Dispensing 247

Drug Topics

DECEMBER 13, 2023

Understanding the adverse event profile of bispecific antibodies can aid treatment selection and improve patient outcomes.

200

200

Drug Topics

APRIL 1, 2024

The can’t-miss event on April 13 features speakers and CE sessions focused on elevating patient-centric care.

144

144

Fierce Healthcare

DECEMBER 27, 2023

A hospital’s acquisition by a private equity firm is linked to a rise in adverse events despite the pool of lower risk patients they tend to admit, according to a Medicare Part A claims analysis pu | Hospital-acquired adverse events among Medicare beneficiaries were 25% higher within the three years after a private equity acquisition compared to control (..)

Hospitals 136

Hospitals 136

STAT

FEBRUARY 19, 2024

The study looked into two cohorts of patients without active heart disease, 60% of whom were treated with statins, and found a strong association between a metabolic product of excess niacin and an increased risk of major adverse cardiovascular events such as a heart attack or stroke. Read the rest…

137

137

PhRMA

APRIL 7, 2023

Ubl spoke recently at The Hill’ s event, “ Pathways to Patient Affordability.” PhRMA president and CEO Stephen J.

Insurance 196

Insurance 196

Pharmacy Times

OCTOBER 17, 2023

Mental health treatment may be necessary when SAEs occur.

65

65

Pharmacy Times

NOVEMBER 10, 2023

The on-demand enzyme replacement therapy reduced acute thrombotic thrombocytopenic purpura events in patients who experience potentially fatal blood clotting.

FDA 123

FDA 123

Pharmacy Times

NOVEMBER 20, 2023

The study authors suggest that future research should instead emphasize event rates and patient-reported outcomes to better evaluate the tolerability and frequency of AEs.

123

123

PhRMA

DECEMBER 9, 2022

On December 7, 2022, PhRMA sponsored the Axios event, “ The Post-Midterm Health Care Agenda ,” where I participated in a View from the Top segment with Nicholas Johnston, publisher of Axios.

Insurance 224

Insurance 224

STAT

MARCH 5, 2024

LONDON — Novo Nordisk’s diabetes medication Ozempic cut the risk of patients developing advanced kidney disease or dying from kidney or heart complications, the company said Tuesday, adding to the evidence the wildly popular drug has broader health benefits for patients beyond addressing their diabetes. and Europe.

Insurance 145

Insurance 145

STAT

MARCH 25, 2024

It was slow to use computers, digitize patient data, and share information electronically. The health care sector is a notorious laggard when it comes to technology. While most of the world instantly interacts via Zoom and Slack, hospitals — even today — are still sending faxes. last week.

Insurance 143

Insurance Hospitals 143

Hospital Pharmacy Europe

APRIL 11, 2024

Kicking off on 1 May 2024, Clinical Excellence in Respiratory Care is a one-day event for the multidisciplinary team exploring the latest advances in respiratory – and registration is now open. With a whole host of fascinating insights and inspiration for improving patient care, it’s not to be missed.

Hospitals 52

Hospitals Patient Care 52

Pharmacy Times

FEBRUARY 6, 2024

Leg compression therapy was associated with decreased brain natriuretic peptide levels without any adverse events for patients with stable chronic heart failure.

81

81

Digital Pharmacist

FEBRUARY 29, 2024

National Nutrition Month is an annual campaign sponsored by the Academy of Nutrition and Dietetics and it’s a great opportunity for local pharmacies to educate their patients on the importance of good nutrition, healthy diets, and exercise.

Health and Personal Care Stores 111

Health and Personal Care Stores 111

STAT

MARCH 14, 2024

Editor’s note: A livestream of this event will be embedded below at 1 p.m. Join leading experts to discuss the impact on the industry and patients. Join leading experts to discuss the impact on the industry and patients. market over the past year.

Insurance Coverage 100

Insurance Coverage Insurance 100

Fierce Pharma

DECEMBER 9, 2023

BCMA-targeted therapies are transforming care for multiple myeloma patients. A new study examined side effect reports of BMCA immunotherapies from the FDA Adverse Event Reporting System, hoping to help inform doctors in their treatment decisions. But these immunotherapies also come with various potentially dangerous side effects. |

FDA 115

FDA 115

Hospital Pharmacy Europe

APRIL 20, 2023

Use of bempedoic acid among statin-intolerant patients reduces the incidence of major adverse cardiovascular events compared to placebo Bempedoic acid (BA) modulates both ATP-citrate lyase and AMP-activated protein kinase activity thereby reducing LDL cholesterol. This was the purpose of the current CLEAR outcomes trial. mmol/L and 3.52

Hospitals 97

Hospitals 97

Pharmacy Times

NOVEMBER 7, 2022

Chlorthalidone was associated with more individuals with potassium levels below 3.1 mmol/L, suggesting a greater risk of hypokalemia.

65

65

Fierce Pharma

JULY 21, 2023

A week after ADC Therapeutics paused its Zynlonta trial to review seven deaths and five other respiratory events in patients who received the drug, the company has scrapped the study altogether fol | After severe respiratory events and seven deaths held up ADC's Zynlonta study in unfit or frail patients with previously untreated diffuse large (..)

FDA 98

FDA 98

STAT

DECEMBER 18, 2023

Editor’s note: A livestream of the event will be embedded below at 1 p.m. Since the development of Gleevec two decades ago, precision cancer medicines have become a driving force in biotech and a source of hope for cancer patients. Read the rest…

108

108

pharmaphorum

DECEMBER 1, 2023

AstraZeneca has decided to abandon two phase 3 trials of its drug to reduce high levels of potassium in the blood (hyperkalaemia) – Lokelma – in patients with kidney disease.

Labelling 104

Labelling 104

Hospital Pharmacy Europe

MARCH 10, 2023

In a randomised, placebo-controlled trial of patients with completely resected stage III melanoma, adjuvant treatment with the programmed death 1 (PD-1) inhibitor, pembrolizumab, significantly improved recurrence-free survival compared to placebo. The primary end point was set as event-free survival in the intention-to-treat population.

Labelling 96

Labelling Hospitals 96

STAT

NOVEMBER 12, 2023

PHILADELPHIA — An investigational drug aimed at preventing strokes significantly reduced the risk of bleeding compared with a commonly used blood thinner for stroke prevention, showing potential to be a safer alternative for patients. Continue to STAT+ to read the full story…

133

133

PharmExec

APRIL 4, 2024

Early results have demonstrated that mRNA-3927 has led to a 70% reduction in the relative risk for metabolic decompensation events in patients with propionic acidemia.

52

52